肿瘤生物学—肝癌、甲状腺癌等多种肿瘤的发病及进展机制；

肿瘤治疗—与材料科学、有机化学交叉发展新型抗肿瘤治疗策略；

内分泌代谢性疾病—甲状旁腺功能亢进的进展机制

2002年-2013年于西安交通大学医学部完成本、硕、博学业，并留院工作，从事肿瘤生物学、肿瘤治疗相关研究。现阶段主要研究肝癌、甲状腺癌进展机制，并与有机化学、材料学合作开展若干肿瘤治疗研究。自博士研究阶段起参与和主持各级各类纵向研究项目31项，其中主持国家自然科学基金2项、省级项目等3项、校/院级项目2项、横向课题2项。研究内容涉及肿瘤生物学、蛋白质表达纯化、转基因动物、生信分析、细胞免疫治疗等技术，具有丰富的科研经历。目前多个在研项目涉及缺氧等诱因下、糖生物学背景下，肿瘤微环境的代谢改变及巨噬细胞、成纤维细胞的功能变化。目前发表SCI论文49篇，其中第一（共同第一）及通讯（共同通讯）作者15篇；被引1097次，H指数21。自博士研究生阶段起带教低年级研究生，工作后作为合作导师协助团队侯鹏教授已培养若干学生获得硕、博士学位，指导本科生获得第33届“腾飞杯”创新创业大赛一等奖，拥有丰富的带教经历和经验。

代表性论著：

1.    Zhang Y, Liang L, Li H, Cao Y, Meng D, Li X, Wang M, Wang J, Yao Y, Zhang S, Chen C*, Hou P*, Yang Q*. Smart multi-functional aggregates reoxygenate tumor microenvironment through a two-pronged strategy to revitalize cancer immunotherapy. Aggregate. 2024. Online published. (IF: 18.8)

2.    Yang Q, Jiang W, Hou P*. Emerging role of PI3K/AKT in tumor-related epigenetic regulation. Semin Cancer Biol. 2019;59:112-124. (IF: 14.5)

3.    Yang Q and Hou P*. Targeting PFKFB3 in the Endothelium for Cancer Therapy. Trends Mol Med. 2017;23(3):197-200. (IF: 13.6)

4.    Ruan B, Liu W, Chen P, Cui R, Li Y, Ji M, Hou P*, Yang Q*. NVP-BEZ235 inhibits thyroid cancer growth by p53- dependent/independent p21 upregulation. International journal of biological sciences 2020; 16: 682-693. (IF:9.2)

5.    Dang S, Zhou J, Chen Y, Chen P, Ji M, Shi B, Yang Q*, Hou P*. Dynamic expression of ZNF382 and its tumor-suppressor role in hepatitis B virus-related hepatocellular carcinogenesis. Oncogene. 2019; 38(24):4804-4819. (IF:8.0)

6.    Yang Q*, Dang H, Liu J, Wang X, Wang J, Lan X, Ji M*, Xing M*, Hou P*. Hypoxia switches TET1 from being tumor-suppressive to oncogenic. Oncogene. 2023; 42(20):1634-8. (IF:8.0)

7.    Wang N, Sui F, Ma J, Su X, Liu J, Yao D, Shi B, Hou P*, Yang Q*. Site-specific Hypermethylation of RUNX3 Predicts Poor Prognosis in Gastric Cancer. Archives of medical research 2016; 47: 285-292. (IF:7.7)

8.    Zhang Y, Zhang Z, Ma J, Pu J, Hou P*, Yang Q*. High-accuracy Detection of Preoperative Thyroid Nodules Using Combination of BRAF(V600E) Mutation and TMPRSS4 mRNA Level. Archives of medical research 2018; 49: 365-372. (IF:7.7)

9.    Cui B^#, Yang Q^#, Guan H, Shi B, Hou P*, Ji M*. PRIMA-1, a Mutant p53 Reactivator, Restores the Sensitivity of TP53 Mutant-type Thyroid Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep). J Clin Endocrinol Metab. 2014; 99(6):E962-70. (IF: 5.8)

10. Yang Q, Ji M, Guan H, Shi B, Hou P*. Shikonin Inhibits Thyroid Cancer Cell Growth and Invasiveness through Targeting Major Signaling Pathways. J Clin Endocrinol Metab. 2013; 98(12):E1909-17. (IF: 5.8)

11. Qui Y^#, Yang Q^#, Sui F, Lu R, Dang S, Ji M, HE N, Shi B, Hou P*. A Strategy for Accurate Quantification of 5-Methylcytosine and 5-Hydroxymethylcytosine at CpG Sites Within Gene Promoter. J Biomed Nanotechnol 2015; 11: 1016-1026. (IF:2.9)

12. Yang Q, Wu K, Ji M, Jin W, He N, Shi B, Hou P*. Decreased 5-hydroxymethylcytosine (5-hmC) is an independent poor prognostic factor in gastric cancer patients. J Biomed Nanotechnol 2013; 9: 1607-1616. (IF:2.9)

13. Yang Q, Shao Y, Shi J, Qu Y, Wu K, Dang S, Shi B, Hou P*. Concomitant PIK3CA amplification and RASSF1A or PAX6 hypermethylation predict worse survival in gastric cancer. Clinical biochemistry 2014; 47: 111-116. (IF:2.8)

14. Li X, Pu J, Liu J, Chen Y, Li Y, Hou P, Shi B, Yang Q*. The prognostic value of DAPK1 hypermethylation in gliomas: A site-specific analysis. Pathology, research and practice 2018; 214: 940-948. (IF:2.8)

15. Lv Y, Zhang Y, Li X, Ren X, Wang M, Tian S, Hou P, Shi B, Yang Q*. Long telomere length predicts poor clinical outcome in esophageal cancer patients. Pathology, research and practice 2017; 213: 113-118. (IF:2.8)

科研获奖：

2019.01 陕西省科学技术二等奖（排名第二）

人才称号：

陕西省青年科技新星（2019年）

电子邮箱：yangqi2015@xjtu.edu.cn

联系电话：